Document Detail

Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate.
MedLine Citation:
PMID:  19440813     Owner:  NLM     Status:  MEDLINE    
The aim was to determine the efficacy of low-dose intermittent pulse administration of mizoribine (MZR), a purine synthesis inhibitor, in combination with methotrexate (MTX) to control the symptoms of rheumatoid arthritis (RA) in patients with an insufficient clinical response to MTX alone. Twenty-seven patients with active RA, despite treatment with MTX, were enrolled and given MZR in combination with MTX and continued for 24 weeks. The primary endpoint was assessment of clinical improvements using the European League against Rheumatism (EULAR) criteria. Administering MZR to RA patients with an insufficient response to MTX produced significant improvements in the Disease Activity Score 28 (DAS28) after 8-24 weeks. In addition, after 24 weeks, 60.0% and 8.0% of patients had achieved moderate and good responses, respectively, and there were significant reductions in Modified Health Assessment Questionnaire and serum matrix metalloproteinase-3 levels. The present preliminary study suggests that low-dose MZR in combination with MTX is well tolerated and provides both clinical and economic benefits.
Tsuyoshi Kasama; Kuninobu Wakabayashi; Tsuyoshi Odai; Takeo Isozaki; Mizuho Matsunawa; Nobuyuki Yajima; Yusuke Miwa; Masao Negishi; Hirotsugu Ide
Related Documents :
23375563 - Florbetapir (f18-av-45) pet to assess amyloid burden in alzheimer's disease dementia, m...
24839913 - Clinical profiles of dementia with lewy bodies with and without alzheimer's disease-lik...
16778623 - Septal lines in pleural inflammation: multidetector computed tomography findings in 30 ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-05-14
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  19     ISSN:  1439-7595     ISO Abbreviation:  Mod Rheumatol     Publication Date:  2009  
Date Detail:
Created Date:  2009-08-04     Completed Date:  2009-11-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  395-400     Citation Subset:  IM    
Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Arthritis, Rheumatoid / blood,  drug therapy*,  physiopathology
C-Reactive Protein / analysis
Dose-Response Relationship, Drug
Drug Resistance / drug effects*
Drug Therapy, Combination
Health Status
Joints / drug effects,  physiopathology
Matrix Metalloproteinase 3 / blood
Methotrexate / therapeutic use*
Middle Aged
Prospective Studies
Ribonucleosides / therapeutic use*
Severity of Illness Index
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Ribonucleosides; 50924-49-7/bredinin; 59-05-2/Methotrexate; 9007-41-4/C-Reactive Protein; EC Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short-term and long-term outcome of endoluminal gastroplication for the treatment of GERD: the first...
Next Document:  Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in...